Skip to main content
. Author manuscript; available in PMC: 2021 Jul 8.
Published in final edited form as: Thromb Res. 2021 Jan 18;200:64–71. doi: 10.1016/j.thromres.2021.01.006

Fig. 3.

Fig. 3.

Platelet exposure to ASOs leads to decrease in platelet numbers ex vivo. A. Platelet concentration of healthy donor platelets (n = 10, line connects the same donor across experiments) before and after exposure to PS-ASO (16 μM or 24 μM) (upper panel) or to or ME/PS-ASO (16 μM or 24 μM) (lower panel). A significant decrease in the number of platelets was observed after the addition of an ASO-type molecules. **p = 0.004, **p = ***p < 0.001 B. Platelet concentrations in patients with prostate cancer (n = 9) before and after exposure to PS-ASO (24 μM) (upper panel), or ME/PS-ASO (24 μM) (lower panel). A significant decrease in the number of platelets was observed after the addition of ASO-type molecules; PS-ASO *p = 0.041, ME/PS-ASO *p = 0.015.